The body of knowledge required to predict if AMBS technical/clinical concepts can ever turn into real products and revenue is massive and at some level unknowable. In the context of investing and planning some will look for assurances from other pieces of information. For example; what is the likelihood that this team and BOD would nucleate in the wrong place? How likely is it that ALL of the plans will fall apart and no good will come, ever? (and so forth) How important and beneficial are the possible outcomes?
Owning mass quantities of AMBS presents odds a little better than picking a winning lottery ticket. But, it also potentially means progress for AD, TBI, forms of autism, vision loss, severe burns and a long list of other patient disorders we do not even know about. Best Thanksgiving to all.
And...The Patriots win the super bowl this year.
I see this news as the first real set of factual information reported by AMBS. Many PR on potential and "gonna-be great", but this is first proof. Lympro will hopefully deliver similar facts soon which talk to clinical-objective evidence of real value. We needed this.
Like the man said...all the best...bodes well for patients and hard work to come by our research teams. Does this signify the end of the beginning?
BTW, I sincerely hope the military sponsors and potential patients w/TBI and severe burns hang in with this. I am also in NVIV for similar reasons. It is a win/win, if we win/the patients will win.
Yup, obviously they are linked but either can move on it's own. The AMBS-RGIN DNA looks positive for sure considering history of drivers. It is a #$%$ shoot but with massive potential.
Jun-12-2012 FDA Issues Orphan Status Approval for PermaDerm®
LITTLE FALLS, N.J., June 6, 2012 /PRNewswire/ -- Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs, announced today that the Food and Drug Administration (FDA) has granted Orphan Status approval for the PermaDerm® product, the only tissue-engineered skin prepared from autologous (patient’s own) skin cells consisting of both epidermal and dermal layers, that is indicated for catastrophic burn patients. The FDA had previously designated PermaDerm® to be a biological/drug (permanent skin replacement) not a medical device (temporary skin replacement). PermaDerm® is the only skin replacement technology to receive this Biological/drug designation.
Well, it is obviously a set-up to get you going again. The results are either already in compilation- done or he is nuts and totally irresponsible. I think you broke the code.
Could you read 1MM as a holding number? Just to indicate some num but up for adjustment as required...that is how I read it...as...=somnum. No more , no less. Just let it be...he could have written an expression but chose not to.
Since AZ brains are required to establish the validation. I wondered when, how they started the study to support such a (10 year) claim.
Time lines suggest a certain discipline which in AMBS case is a great concept but, as we all know by now, has a dark side. Great concept but when used in a research-development environment has a long term unintended consequence.